Global Immune Checkpoint Agents Market Insights, Forecast to 2025
Table of Contents
1 Study Coverage
- 1.1 Immune Checkpoint Agents Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Immune Checkpoint Agents Market Size Growth Rate by Product
- 1.4.2 Anti-PD-L1 Drug
- 1.4.3 Anti-PD-1 Drug
- 1.4.4 CTLA4
- 1.5 Market by End User
- 1.5.1 Global Immune Checkpoint Agents Market Size Growth Rate by End User
- 1.5.2 Lung Cancer
- 1.5.3 Colorectal Cancer
- 1.5.4 Breast Cancer
- 1.5.5 Prostate Cancer
- 1.5.6 Melanoma
- 1.5.7 Blood Cancers
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Immune Checkpoint Agents Market Size
- 2.1.1 Global Immune Checkpoint Agents Revenue 2014-2025
- 2.1.2 Global Immune Checkpoint Agents Sales 2014-2025
- 2.2 Immune Checkpoint Agents Growth Rate by Regions
- 2.2.1 Global Immune Checkpoint Agents Sales by Regions
- 2.2.2 Global Immune Checkpoint Agents Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Immune Checkpoint Agents Sales by Manufacturers
- 3.1.1 Immune Checkpoint Agents Sales by Manufacturers
- 3.1.2 Immune Checkpoint Agents Sales Market Share by Manufacturers
- 3.1.3 Global Immune Checkpoint Agents Market Concentration Ratio (CR5 and HHI)
- 3.2 Immune Checkpoint Agents Revenue by Manufacturers
- 3.2.1 Immune Checkpoint Agents Revenue by Manufacturers (2014-2019)
- 3.2.2 Immune Checkpoint Agents Revenue Share by Manufacturers (2014-2019)
- 3.3 Immune Checkpoint Agents Price by Manufacturers
- 3.4 Immune Checkpoint Agents Manufacturing Base Distribution, Product Types
- 3.4.1 Immune Checkpoint Agents Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Immune Checkpoint Agents Product Type
- 3.4.3 Date of International Manufacturers Enter into Immune Checkpoint Agents Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Immune Checkpoint Agents Sales by Product
- 4.2 Global Immune Checkpoint Agents Revenue by Product
- 4.3 Immune Checkpoint Agents Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Immune Checkpoint Agents Breakdown Data by End User
6 North America
- 6.1 North America Immune Checkpoint Agents by Countries
- 6.1.1 North America Immune Checkpoint Agents Sales by Countries
- 6.1.2 North America Immune Checkpoint Agents Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Immune Checkpoint Agents by Product
- 6.3 North America Immune Checkpoint Agents by End User
7 Europe
- 7.1 Europe Immune Checkpoint Agents by Countries
- 7.1.1 Europe Immune Checkpoint Agents Sales by Countries
- 7.1.2 Europe Immune Checkpoint Agents Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Immune Checkpoint Agents by Product
- 7.3 Europe Immune Checkpoint Agents by End User
8 Asia Pacific
- 8.1 Asia Pacific Immune Checkpoint Agents by Countries
- 8.1.1 Asia Pacific Immune Checkpoint Agents Sales by Countries
- 8.1.2 Asia Pacific Immune Checkpoint Agents Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Immune Checkpoint Agents by Product
- 8.3 Asia Pacific Immune Checkpoint Agents by End User
9 Central & South America
- 9.1 Central & South America Immune Checkpoint Agents by Countries
- 9.1.1 Central & South America Immune Checkpoint Agents Sales by Countries
- 9.1.2 Central & South America Immune Checkpoint Agents Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Immune Checkpoint Agents by Product
- 9.3 Central & South America Immune Checkpoint Agents by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Immune Checkpoint Agents by Countries
- 10.1.1 Middle East and Africa Immune Checkpoint Agents Sales by Countries
- 10.1.2 Middle East and Africa Immune Checkpoint Agents Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Immune Checkpoint Agents by Product
- 10.3 Middle East and Africa Immune Checkpoint Agents by End User
11 Company Profiles
- 11.1 Bristol Myers Squibb
- 11.1.1 Bristol Myers Squibb Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Bristol Myers Squibb Immune Checkpoint Agents Products Offered
- 11.1.5 Bristol Myers Squibb Recent Development
- 11.2 Merck
- 11.2.1 Merck Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Merck Immune Checkpoint Agents Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Merck Immune Checkpoint Agents Products Offered
- 11.2.5 Merck Recent Development
- 11.3 AstraZeneca
- 11.3.1 AstraZeneca Company Details
- 11.3.2 Company Business Overview
- 11.3.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 AstraZeneca Immune Checkpoint Agents Products Offered
- 11.3.5 AstraZeneca Recent Development
- 11.4 Roche
- 11.4.1 Roche Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Roche Immune Checkpoint Agents Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Roche Immune Checkpoint Agents Products Offered
- 11.4.5 Roche Recent Development
12 Future Forecast
- 12.1 Immune Checkpoint Agents Market Forecast by Regions
- 12.1.1 Global Immune Checkpoint Agents Sales Forecast by Regions 2019-2025
- 12.1.2 Global Immune Checkpoint Agents Revenue Forecast by Regions 2019-2025
- 12.2 Immune Checkpoint Agents Market Forecast by Product
- 12.2.1 Global Immune Checkpoint Agents Sales Forecast by Product 2019-2025
- 12.2.2 Global Immune Checkpoint Agents Revenue Forecast by Product 2019-2025
- 12.3 Immune Checkpoint Agents Market Forecast by End User
- 12.4 North America Immune Checkpoint Agents Forecast
- 12.5 Europe Immune Checkpoint Agents Forecast
- 12.6 Asia Pacific Immune Checkpoint Agents Forecast
- 12.7 Central & South America Immune Checkpoint Agents Forecast
- 12.8 Middle East and Africa Immune Checkpoint Agents Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Immune Checkpoint Agents Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
The global Immune Checkpoint Agents market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Immune Checkpoint Agents market based on company, product type, end user and key regions.
This report studies the global market size of Immune Checkpoint Agents in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Immune Checkpoint Agents in these regions.
This research report categorizes the global Immune Checkpoint Agents market by top players/brands, region, type and end user. This report also studies the global Immune Checkpoint Agents market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Bristol Myers Squibb
Merck
AstraZeneca
Roche
Market size by Product
Anti-PD-L1 Drug
Anti-PD-1 Drug
CTLA4
Market size by End User
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancers
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Immune Checkpoint Agents market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Immune Checkpoint Agents market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Immune Checkpoint Agents companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Immune Checkpoint Agents submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Immune Checkpoint Agents are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Immune Checkpoint Agents market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.